Defining the Bioaccumulation Gap
The relationship between drinking water PFAS concentration and the resulting tissue or serum burden is not linear or uniform across PFAS compounds. Several PFAS compounds exhibit a “bioaccumulation gap” — a phenomenon in which relatively low drinking water concentrations produce disproportionately high tissue concentrations, either because of high tissue affinity, long elimination half-lives, specific transport mechanisms that actively concentrate the compound in particular organs, or all three. Understanding which PFAS compounds exhibit this behavior is essential for interpreting biomonitoring data and for identifying settings where standard risk metrics derived from water concentration alone may underestimate actual tissue exposure.
The most straightforward expression of bioaccumulation potential is the bioaccumulation factor (BAF) — the ratio of tissue or serum concentration to water concentration at steady state. For PFOA and PFOS, BAFs in humans are relatively well-characterized and have been incorporated into toxicokinetic models used for MCL derivation. For many newer PFAS compounds, particularly fluorotelomer-based compounds and certain sulfonamide derivatives, BAF data in humans are either sparse or absent, creating a gap in the exposure assessment framework.
Long-Chain PFAS and Liver Accumulation
Among well-characterized PFAS, the perfluoroalkyl carboxylates and sulfonates with chain lengths above C7 show strong affinity for liver tissue due to binding with liver fatty acid binding proteins and peroxisome proliferator-activated receptor alpha (PPARα). Post-mortem tissue studies and surgical biopsy data have found liver-to-serum PFAS concentration ratios substantially above 1.0 for PFOA, PFOS, and particularly for longer-chain compounds such as PFDA (C10) and PFUnDA (C11). Liver accumulation is toxicologically significant because the liver is both a primary target for PFAS toxicity and the site of precursor PFAS biotransformation, meaning that hepatic PFAS concentrations exceed serum concentrations at the same time that the liver is producing additional PFAA metabolites from precursor compounds.
Thyroid tissue represents another documented bioaccumulation site for certain PFAS compounds. Studies in rodent models have found thyroid gland PFAS concentrations substantially exceeding serum levels, consistent with active uptake via thyroid hormone transport proteins. This tissue-level concentration amplifies the biological potency of thyroid-disrupting PFAS at the receptor level beyond what serum PFAS data alone would suggest.
Kidney Concentration Dynamics for Short-Chain PFAS
As noted in the PFBS toxicology literature, the kidney presents a counterintuitive bioaccumulation scenario for certain short-chain PFAS. Despite faster overall elimination from the body, some short-chain compounds undergo active tubular secretion mechanisms that transiently concentrate them in renal tissue during the elimination process. The organic anion transporter (OAT) system, which handles the renal secretion of many PFAS compounds, varies in its affinity for different chain lengths and functional groups, creating compound-specific renal concentration patterns.
For PFBS specifically, pharmacokinetic studies in rodents have documented renal concentrations exceeding serum concentrations during the excretion phase — a dynamic that may explain the kidney as the primary toxicological target organ despite the compound’s overall faster elimination. If analogous concentration dynamics occur in humans at environmentally relevant drinking water exposures, the kidney tissue dose from PFBS may be higher than serum biomonitoring data suggest, with implications for risk assessment models that use serum concentration as the dose metric.
Implications for Biomonitoring Interpretation
The practical consequence of tissue-selective PFAS bioaccumulation is that serum PFAS concentrations — the primary output of large-scale biomonitoring programs such as the U.S. NHANES — are necessary but insufficient for characterizing the full body burden and tissue-level exposure driving health effects. A person with moderate serum PFAS levels but high hepatic or renal PFAS tissue concentrations due to compound-specific accumulation dynamics may be at higher effective biological exposure than their serum data suggests.
This limitation is not easily resolved in population biomonitoring contexts, where organ tissue sampling is impractical. However, it underscores the importance of using serum biomonitoring data alongside mechanistic pharmacokinetic models — rather than in isolation — when making individual or population-level risk determinations. For communities evaluating whether a water treatment intervention has been protective, the multi-year lag between serum concentration reduction and tissue burden reduction for long-chain, high-BAF compounds should be communicated clearly: reduced water exposure does not immediately translate to reduced body burden for compounds like PFOS with multi-year tissue half-lives.